COPD market seen reaching $72.55 billion by 2035

Market Research Future says the global COPD market is projected to more than double by 2035, reaching $72.55 billion from $32.10 billion in 2025. The forecast points to rising COPD prevalence, wider use of triple-combination inhalers, biologics and connected monitoring as the main growth drivers.

Why it matters: - COPD treatment is moving toward more expensive and more effective maintenance care, which could lift spending across drugs, devices and digital monitoring. - The forecast reflects a larger shift in chronic respiratory care toward earlier intervention, better adherence and home-based management. - The market opportunity is also expanding as more patients are diagnosed and more health systems reimburse connected care.

What happened: - Market Research Future projected the global COPD market to reach $72.55 billion by 2035, up from $32.10 billion in 2025. - The forecast implies growth from $34.82 billion in 2026 to the 2035 endpoint. - The company estimated an 8.50% compound annual growth rate for 2025-2035. - The report linked the outlook to rising disease prevalence, triple-combination inhalers and biologic therapies. - The report also highlighted connected health tools such as smart inhalers and remote patient monitoring.

The details: - COPD affects more than 480 million adults worldwide, according to the WHO's 2024 Global Burden of Disease update. - Single-inhaler triple therapy is gaining share as clinicians move earlier to fixed-dose LABA/LAMA/ICS products. - Global single-inhaler triple therapy revenue topped $8.9 billion in 2024. - Formulary coverage for triple therapy spans more than 85% of U.S. commercial health plans. - Triple therapy has expanded average prescription values by about 40% over three years. - Sanofi and Regeneron's dupilumab became the first FDA-approved biologic for COPD in September 2024. - The biologics pipeline also includes anti-IL-4/IL-13, anti-IL-5, anti-TSLP and anti-IL-33 approaches. - The report expects $3 billion to $5 billion in new biologic spending by 2030. - Premium biologic pricing is projected at $15,000 to $25,000 per patient per year. - Bluetooth-enabled inhaler sensors and remote spirometry platforms are being used to track adherence and spot exacerbations earlier. - Real-world evidence published in The Lancet Respiratory Medicine showed a 58% improvement in adherence among connected-inhaler users. - CMS finalized reimbursement codes for Remote Patient Monitoring of chronic respiratory conditions, including CPT 99457 and CPT 99458. - North America led the market with 40.80% of global revenue, or about $13.1 billion. - Europe accounted for an estimated $9.15 billion in 2024, or 28.50% of the market. - Asia-Pacific was the fastest-growing region at a 7.90% CAGR. - South America was valued at $1.98 billion in 2024. - The Middle East and Africa region is projected to grow at a 5.80% CAGR. - Drug class therapies held the largest product share at 69.50% in 2024. - Monitoring devices were the fastest-growing product segment at a 9.60% CAGR through 2035. - Hospitals and clinics made up the largest end-user segment with 83.30% share in 2024. - Homecare settings were the fastest-growing end-user segment at a 7.30% CAGR through 2035.

Between the lines: - The forecast suggests COPD is becoming a platform market, with growth spread across inhalers, biologics, monitoring devices and reimbursement-backed digital care. - The strongest demand appears to be in therapies that improve adherence and reduce exacerbations, not just symptom relief. - Environmental regulation is also reshaping inhaler design, adding costs but opening another innovation cycle. - The report signals that market growth will likely depend as much on diagnostics and access as on drug innovation.

What's next: - The report expects biologics to expand beyond eosinophilic COPD into other inflammatory phenotypes. - It also sees growth in AI-enabled exacerbation prediction tools and digital therapeutics. - Investment in spirometry infrastructure in emerging markets could unlock more diagnosed patients. - Low-GWP inhaler reformulations are likely to stay a priority through the decade. - Market Research Future offered a free sample, customization request and detailed report.

The bottom line: - COPD care is shifting toward premium therapies, connected monitoring and precision medicine, and the market is forecast to reflect that shift through 2035.